Compare ADMA Biologics Inc (ADMA) vs General Mills, Inc. (GIS) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ADMA Biologics Inc vs General Mills, Inc. — how do they compare? ADMA Biologics Inc trades at $9.22 (market cap $2.13B), while General Mills, Inc. trades at $36.54 (market cap $19.80B). The key difference: General Mills, Inc. is far larger — about 9.3× ADMA Biologics Inc's market cap, and General Mills, Inc. pays a 6.58% dividend while ADMA Biologics Inc pays none. Which is the better fit depends on your goals.
| ADMA | GIS | |
|---|---|---|
Market Cap | $2.13B | $19.80B |
Sector | Health | Consumer Staples |
52-Week High | $20.38 | $51.84 |
52-Week Low | $7.60 | $32.17 |
Enterprise Value | $2.20B | $33.29B |
Dividend Yield | — | 6.58% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.16, up 2.35% today, with a bullish technical signal from moving averages and oscillators. The company reported strong profitability with a 32.43% net income margin and 43.3% ROE for 2025, though recent EPS results were mixed. Analyst consensus is strongly bullish with an $19.00 price target, but multiple class action lawsuits filed in July 2026 alleging securities fraud create significant near-term uncertainty.
The stock offers substantial upside to analyst targets if legal challenges are resolved favorably, supported by robust fundamentals and projected cash flow growth. Primary risks include the outcome of ongoing litigation and potential reputational damage. Investors should weigh strong financial performance against elevated legal and sentiment risks before establishing a position.
General Mills (GIS) trades at $37.10, down 1.25% on the day, with a bullish technical signal from moving averages and a neutral RSI near 58. The stock shows mixed earnings performance, beating Q2 2026 estimates but missing in Q4 2025, while revenue has declined from $20.1B in 2023 to $19.5B in 2025. The company maintains a dividend of $0.61 per share and is implementing cost-saving initiatives targeting $3B by 2030 to counter margin pressures from private-label competition.
Outlook: GIS presents a value opportunity with a low P/E of 9.23, but faces headwinds from sluggish sales and negative net income margin. Risks include consumer spending shifts and high debt levels. Analyst consensus is cautious with a hold-heavy rating and a $36.14 price target slightly below current levels, suggesting limited near-term upside without stronger earnings growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ADMA Biologics Inc
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →About General Mills, Inc.
General Mills is a leading global packaged food company that produces snacks, cereal, convenient meals, yogurt, dough, baking mixes and ingredients, pet food, and superpremium ice cream. Its largest brands are Nature Valley, Cheerios, Old El Paso, Yoplait, Pillsbury, Betty Crocker, BLUE, and Haagen-Dazs. In fiscal 2022, 77% of its revenue was derived from the United States, although the company also operates in Canada, Europe, Australia, Asia, and Latin America. While most of General Mills' products are sold through retail stores to consumers, the company also sells products into the food-service channel and the commercial baking industry.
Read more on GIS →
